EPOR and cancer: For example, tumor cells has been shown to express considerably lower levels of EPOR than erythroid progenitor cells (Swift et al., 2010), and aside from the “classical” EPOR homodimer form, usually detected on erythroid cells, either a heteroreceptor consisting of EPOR and common beta receptor (EPOR/βcR) or Ephrin B4 receptor (EPHB4) has also been identified as EPO-binding receptor in cancer cells (Arcasoy et al., 2002; Pradeep et al., 2015).